Leah Isakov

712 total citations
16 papers, 515 citations indexed

About

Leah Isakov is a scholar working on Epidemiology, Immunology and Economics and Econometrics. According to data from OpenAlex, Leah Isakov has authored 16 papers receiving a total of 515 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Epidemiology, 7 papers in Immunology and 5 papers in Economics and Econometrics. Recurrent topics in Leah Isakov's work include Health Systems, Economic Evaluations, Quality of Life (5 papers), Influenza Virus Research Studies (4 papers) and Respiratory viral infections research (3 papers). Leah Isakov is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (5 papers), Influenza Virus Research Studies (4 papers) and Respiratory viral infections research (3 papers). Leah Isakov collaborates with scholars based in United States, Poland and Russia. Leah Isakov's co-authors include Ira Jacobs, Christopher G. Wood, Pramod K. Srivastava, Bernard Escudier, Gorelov Ai, Henryk Zieliński, Louis Lacombe, Florentina Teofilovici, Robert A. Figlin and Ronald M. Bukowski and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Leah Isakov

13 papers receiving 495 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Leah Isakov United States 10 280 195 151 103 99 16 515
Deepak Assudani United States 12 795 2.8× 118 0.6× 338 2.2× 48 0.5× 75 0.8× 29 1.1k
Rajnish Nagarkar India 12 173 0.6× 141 0.7× 246 1.6× 132 1.3× 82 0.8× 61 665
Elisa Gallerani Switzerland 15 149 0.5× 308 1.6× 427 2.8× 160 1.6× 32 0.3× 42 773
Daniel E. Meyers Canada 15 86 0.3× 108 0.6× 412 2.7× 179 1.7× 44 0.4× 41 618
Rachel Kobos United States 18 98 0.3× 315 1.6× 359 2.4× 97 0.9× 61 0.6× 65 830
Saoirse Dolly United Kingdom 13 76 0.3× 341 1.7× 330 2.2× 179 1.7× 107 1.1× 32 725
Erin L. Schenk United States 18 224 0.8× 303 1.6× 450 3.0× 302 2.9× 50 0.5× 55 843
Brian McClune United States 15 144 0.5× 213 1.1× 323 2.1× 25 0.2× 36 0.4× 68 998
Amit Sud United Kingdom 15 68 0.2× 361 1.9× 244 1.6× 102 1.0× 108 1.1× 37 962
Kartik Sehgal United States 15 184 0.7× 235 1.2× 388 2.6× 222 2.2× 71 0.7× 50 765

Countries citing papers authored by Leah Isakov

Since Specialization
Citations

This map shows the geographic impact of Leah Isakov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leah Isakov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leah Isakov more than expected).

Fields of papers citing papers by Leah Isakov

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leah Isakov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leah Isakov. The network helps show where Leah Isakov may publish in the future.

Co-authorship network of co-authors of Leah Isakov

This figure shows the co-authorship network connecting the top 25 collaborators of Leah Isakov. A scholar is included among the top collaborators of Leah Isakov based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leah Isakov. Leah Isakov is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
2.
Takáč, Peter, Radka Michalková, Zdenka Bedlovičová, et al.. (2025). Do We Know Enough About the Safety Profile of Silver Nanoparticles in Oncology? A Focus on Novel Methods and Approaches. International Journal of Molecular Sciences. 26(11). 5344–5344.
3.
4.
5.
Berry, Donald A., Scott Berry, Leah Isakov, et al.. (2020). A cost/benefit analysis of clinical trial designs for COVID-19 vaccine candidates. PLoS ONE. 15(12). e0244418–e0244418. 17 indexed citations
6.
Isakov, Leah, et al.. (2019). Is the FDA too conservative or too aggressive?: A Bayesian decision analysis of clinical trial design. Journal of Econometrics. 211(1). 117–136. 28 indexed citations
7.
8.
9.
Simoens, Steven, et al.. (2017). Assessing the Value of Biosimilars: A Review of the Role of Budget Impact Analysis. PharmacoEconomics. 35(10). 1047–1062. 36 indexed citations
10.
Jacobs, Ira, Danielle Petersel, Leah Isakov, Sadiq Lula, & K. Lea Sewell. (2016). Biosimilars for the Treatment of Chronic Inflammatory Diseases: A Systematic Review of Published Evidence. BioDrugs. 30(6). 525–570. 35 indexed citations
11.
Isakov, Leah, Bo Jin, & Ira Jacobs. (2016). Statistical Primer on Biosimilar Clinical Development. American Journal of Therapeutics. 23(6). e1903–e1910. 22 indexed citations
12.
Isakov, Leah, et al.. (2015). Structure and dynamics of congenital maxillofacial malformations in Yakutiya region. Stomatology. 94(2). 37–37. 3 indexed citations
13.
Wood, C. G., Priyanka Srivastava, Louis Lacombe, et al.. (2009). Survival update from a multicenter, randomized, phase III trial of vitespen versus observation as adjuvant therapy for renal cell carcinoma in patients at high risk of recurrence. Journal of Clinical Oncology. 27(15_suppl). 3009–3009. 12 indexed citations
14.
Jonasch, Eric, Christopher G. Wood, Pheroze Tamboli, et al.. (2008). Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings. British Journal of Cancer. 98(8). 1336–1341. 44 indexed citations
15.
16.
Santis, George, et al.. (2008). Phase II feasibility study of autologous vaccine (HSPPC-96) in patients with resectable lung cancer. Journal of Clinical Oncology. 26(15_suppl). 7584–7584. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Deepak Assudani Breakdown of academic impact, for papers by Rajnish Nagarkar Breakdown of academic impact, for papers by Elisa Gallerani Breakdown of academic impact, for papers by Daniel E. Meyers Breakdown of academic impact, for papers by Rachel Kobos Breakdown of academic impact, for papers by Saoirse Dolly Breakdown of academic impact, for papers by Erin L. Schenk Breakdown of academic impact, for papers by Brian McClune Breakdown of academic impact, for papers by Amit Sud Breakdown of academic impact, for papers by Kartik Sehgal
Rankless by CCL
2026